repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
Company profile
Ticker
RGEN
Exchange
Website
CEO
Anthony Hunt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Acorda Therapeutics ...
SEC CIK
Corporate docs
Subsidiaries
Repligen Sweden AB • Repligen GmbH • Repligen Singapore Pte. Ltd. • Repligen Europe B.V. • Repligen (Shanghai) Biotechnology Co. Ltd. • Repligen Japan LLC • Repligen India Private Limited • Repligen Korea Co., Ltd. • ARTeSYN Biosolutions Holdings Ireland Ltd. • ARTeSYN Biosolutions Ireland Limited ...
IRS number
42729386
RGEN stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Repligen Reports Third Quarter 2023 Financial Results
31 Oct 23
8-K
Repligen Appoints Olivier Loeillot As President and Chief Commercial Officer
2 Oct 23
8-K
Repligen Announces Agreement to Acquire
26 Sep 23
8-K
Repligen Appoints Jason K. Garland As Chief Financial Officer
12 Sep 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Repligen Reports Second Quarter 2023 Financial Results
2 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 May 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Repligen Reports First Quarter 2023 Financial Results
2 May 23
Transcripts
RGEN
Earnings call transcript
2023 Q3
31 Oct 23
RGEN
Earnings call transcript
2023 Q2
2 Aug 23
RGEN
Earnings call transcript
2023 Q1
2 May 23
RGEN
Earnings call transcript
2022 Q4
22 Feb 23
RGEN
Earnings call transcript
2022 Q3
1 Nov 22
RGEN
Earnings call transcript
2022 Q2
2 Aug 22
RGEN
Earnings call transcript
2022 Q1
27 Apr 22
RGEN
Earnings call transcript
2021 Q4
17 Feb 22
RGEN
Earnings call transcript
2021 Q3
28 Oct 21
RGEN
Earnings call transcript
2021 Q1
27 Jul 21
Latest ownership filings
4
Anthony Hunt
16 Nov 23
4
Christine Gebski
13 Nov 23
144
Notice of proposed sale of securities
13 Nov 23
4
Olivier Loeillot
3 Oct 23
3
Olivier Loeillot
3 Oct 23
4
Jason K Garland
27 Sep 23
3
Jason K Garland
27 Sep 23
4
KAREN A DAWES
30 Aug 23
144
Notice of proposed sale of securities
29 Aug 23
4
Martin D Madaus
22 May 23
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q3 2023
| 13F holders | Current |
|---|---|
| Total holders | 436 |
| Opened positions | 59 |
| Closed positions | 64 |
| Increased positions | 157 |
| Reduced positions | 153 |
| 13F shares | Current |
|---|---|
| Total value | 8.99 tn |
| Total shares | 59.42 mm |
| Total puts | 120.90 k |
| Total calls | 134.80 k |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 7.89 mm | $1.25 tn |
| Vanguard | 5.04 mm | $802.19 bn |
| T. Rowe Price | 3.80 mm | $602.94 bn |
| Eddleman Roy T | 2.71 mm | $0.00 |
| FMR | 2.22 mm | $353.60 bn |
| STT State Street | 1.65 mm | $263.04 bn |
| Sands Capital Management | 1.57 mm | $249.70 bn |
| Artisan Partners Limited Partnership | 1.56 mm | $247.56 bn |
| Brown Capital Management | 1.44 mm | $229.24 bn |
| Wellington Management | 1.40 mm | $222.07 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 Nov 23 | Anthony Hunt | Common Stock | Gift | Dispose G | No | No | 0 | 1,000 | 0.00 | 194,307 |
| 10 Nov 23 | Christine Gebski | Common Stock | Sell | Dispose S | No | No | 147.13 | 3,788 | 557.33 k | 28,787 |
| 2 Oct 23 | Olivier Loeillot | Common Stock | Grant | Acquire A | No | No | 0 | 12,906 | 0.00 | 12,906 |
| 2 Oct 23 | Olivier Loeillot | Stock Option Common Stock | Grant | Acquire A | No | No | 154.96 | 24,236 | 3.76 mm | 24,236 |
News
Benchmark Downgrades Repligen to Hold
4 Dec 23
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
3 Nov 23
Analyst Expectations for Repligen's Future
2 Nov 23
Stifel Maintains Buy on Repligen, Lowers Price Target to $165
1 Nov 23
UBS Maintains Buy on Repligen, Lowers Price Target to $170
1 Nov 23
Press releases
UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report
14 Nov 23
Repligen Announces Publication of the Company's 2022 Sustainability Report
14 Nov 23
Repligen Corporation to Present at Upcoming Investor Conferences
7 Nov 23
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
2 Nov 23
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
31 Oct 23